Concretely: 96.4% · VendorInvestigate · 99.4% · Janoshik.
I would like the axes of comparison first and the recommendation second.
I have tried the first option and it works; the question is whether the second is better rather than merely different.
What is the actual trade-off, and does it matter at the scale I am working at?
96.4 and 99.4 are 3 percentage points apart, which sounds small until you restate it as impurity. VendorInvestigate is leaving 3.6 per cent of the detected area unassigned and Janoshik 0.6 per cent — a factor of 6 between them. The impurity fraction is the quantity that moves when a method changes, and it is the one worth arguing about; the headline is just its complement. Comparable means same column chemistry, same gradient slope, same detection wavelength, same integration convention. Until you have those four from both laboratories, 96.4 and 99.4 are two measurements of slightly different quantities that happen to share a unit.
The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
Compare purity within a single laboratory on the same method, never across laboratories.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsWorth being precise here: identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
More usefully, gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Stated carefully, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Start from what the detector sees, because that tells you what the number means.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.